Bullboard - Stock Discussion Forum Cybin Inc N.CYBN

Alternate Symbol(s): CYBN

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more

Add To Watchlist

Bullboard (NEO:CYBN)

View:

Post by Tardison Mar 14, 2024 8:54am

News - Positive end of phase 2

https://ir.cybin.com/investors/news/news-details/2024/Cybin-Announces-Positive-End-of-Phase-2-Meeting-with-FDA-for-CYB003-in-Major-Depressive-Disorder-and-Phase-3-Program-Design/default.aspx Tight ...more

112

Post by Tardison Mar 13, 2024 2:07pm

Market Taking The Big Raise Well

Just has to fill that small trading gap. https://ir.cybin.com/investors/news/news-details/2024/Announces-Oversubscribed-Private-Placement-of-U.S.-150-Million/default.aspx Still holding since Small ...more

143

Post by BryceCanadaon Mar 07, 2024 6:58pm

Excellent coverage on CYBN!!

https://youtu.be/uW0vvAkSo18?si=efXVdd8f0bVqOrFV

133

(0)
•••

Post by PressReleaseon Dec 06, 2023 7:30am

New Press Release - Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program

- Newly issued patent expected to provide protection until at least 2041 and includes composition of matter claims to pharmaceutical compositions within the Company’s proprietary CYB003 deuterated psilocybin analog program -- Cybin’s patent portfolio now includes 39 granted patents and over 170...read article.

(0)
•••

Post by PressReleaseon Dec 05, 2023 7:30am

New Press Release - Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results

- Poster presentations highlight data across Cybin’s CYB003 and deuterated DMT clinical programs, as well as preclinical development programs - Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental...read article.

(0)
•••

Post by PressReleaseon Nov 30, 2023 7:30am

New Press Release - Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

- Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental benefit of a second dose -- Primary efficacy endpoint achieved with an impressive mean -14 point difference in Montgomery-Asberg Depression Rating Scale...read article.

(0)
•••

Post by PressReleaseon Nov 20, 2023 7:31am

New Press Release - Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

- Company speakers include Doug Drysdale, Chief Executive Officer; and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer -- Featured key opinion leaders include Dr. Maurizio Fava, M.D., Massachusetts General Hospital and Harvard Medical School; and Dr. Gitte Moos Knudsen, Professor...read article.

Post by thorgb1on Nov 16, 2023 12:04pm

News: Phase 2 Topline Safety and Efficacy Data for CYB003

Has to be very positive for them to be scheduling an investor briefing..... News here: Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host ...more

168

(0)
•••

Post by PressReleaseon Nov 16, 2023 7:32am